Weiss Ratings Reiterates Sell (D-) Rating for SELLAS Life Sciences Group (NASDAQ:SLS)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for SELLAS Life Sciences Group (NASDAQ:SLS), indicating ongoing negative sentiment from analysts.
• Maxim Group upgraded the stock to a "Buy" rating, raising its price target from $4.00 to $7.00, amidst a current consensus rating of "Hold."
• SELLAS Life Sciences Group is focusing on the development of novel cancer immunotherapies, with its lead candidate in Phase 3 clinical trials for treating acute myeloid leukemia.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Maxim Group lifted their price objective on shares of SELLAS Life Sciences Group from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $7.00.

SELLAS Life Sciences Group Trading Up 1.6%

SELLAS Life Sciences Group stock opened at $1.93 on Wednesday. SELLAS Life Sciences Group has a 1-year low of $0.77 and a 1-year high of $2.27. The firm has a market capitalization of $203.23 million, a price-to-earnings ratio of -6.03 and a beta of 2.62. The firm has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $1.64.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. On average, equities research analysts forecast that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Virtu Financial LLC grew its position in shares of SELLAS Life Sciences Group by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. Blair William & Co. IL purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $35,000. ProShare Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $43,000. Simon Quick Advisors LLC purchased a new position in SELLAS Life Sciences Group in the second quarter worth $44,000. Finally, Great Valley Advisor Group Inc. purchased a new position in SELLAS Life Sciences Group in the second quarter worth $44,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.